Expanding HIF Prolyl Hydroxylase Inhibitors to New Therapeutic Applications

Publication ID: 24-11857543_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding HIF Prolyl Hydroxylase Inhibitors to New Therapeutic Applications,” Published Technical Disclosure No. 24-11857543_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857543_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,543.

Summary of the Inventive Concept

The present inventive concept explores novel uses of HIF prolyl hydroxylase inhibitors beyond anemia treatment, targeting athletic performance, cognitive function, fatigue reduction, sleep quality, and muscle recovery.

Background and Problem Solved

The original patent focused on treating anemia secondary to chronic kidney disease, chemotherapy, and AIDS. However, the limitations of this patent lie in its narrow scope, neglecting potential applications in other fields. The present inventive concept addresses this limitation by applying HIF prolyl hydroxylase inhibitors to entirely new therapeutic areas.

Detailed Description of the Inventive Concept

The new claims introduce novel uses of HIF prolyl hydroxylase inhibitors in various fields. For instance, Claim 1 proposes a system for monitoring and optimizing athletic performance by administering the inhibitor and measuring hemoglobin levels. Similarly, Claims 2-5 explore the inhibitor's potential in enhancing cognitive function, reducing fatigue, improving sleep quality, and enhancing muscle recovery. These new applications leverage the inhibitor's ability to modulate HIF signaling pathways, unlocking new therapeutic possibilities.

Novelty and Inventive Step

The inventive concept's novelty lies in its unexpected application of HIF prolyl hydroxylase inhibitors to new therapeutic areas, demonstrating an inventive step beyond the original patent's scope. The new claims introduce a paradigm shift in the understanding of the inhibitor's potential, moving beyond anemia treatment to address unmet needs in various fields.

Alternative Embodiments and Variations

Alternative embodiments may include varying the dosage, administration route, or composition of the HIF prolyl hydroxylase inhibitor. Additionally, the inventive concept could be adapted to other diseases or conditions where HIF signaling plays a crucial role, such as cancer, cardiovascular disease, or neurodegenerative disorders.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential, targeting lucrative markets in athletic performance, cognitive function, and chronic disease management. The potential market size is substantial, with opportunities for partnerships, licensing, and product development in various industries.

Field of Art

Pharmaceutical biotechnology, specifically HIF prolyl hydroxylase inhibitor applications in medical treatment and performance enhancement

Person of Ordinary Skill (PHOSITA) Profile

A person with advanced degree in pharmacology or biochemistry, understanding of HIF signaling pathways, experience in drug development, and knowledge of physiological responses to hypoxia-related interventions

Obviousness Rationale

A PHOSITA would recognize that HIF prolyl hydroxylase inhibitors fundamentally modulate oxygen-sensing mechanisms, suggesting potential applications beyond anemia treatment. The source patent establishes the core mechanism of enhancing hemoglobin production, which naturally implies broader physiological performance implications. Given the well-understood signaling pathways, extending the inhibitor's use to performance, cognitive, and recovery domains represents a predictable technological progression.

Obvious Combinations & Variations

Source Patent Element
Method of treating anemia by modulating HIF signaling through prolyl hydroxylase inhibition
PTD Variation
Applying the same inhibitor mechanism to enhance athletic performance and muscle recovery
Obviousness Reasoning
Predictable extension of known physiological mechanism, where increased hemoglobin and oxygen utilization directly correlates with performance enhancement
Source Patent Element
Oral administration of HIF prolyl hydroxylase inhibitor for treating chronic kidney disease-related anemia
PTD Variation
Oral administration for cognitive function and fatigue reduction in different patient populations
Obviousness Reasoning
Known pharmaceutical formulation with established safety profile, representing a routine adaptation of existing drug delivery method
Source Patent Element
Targeting specific disease states through HIF pathway modulation
PTD Variation
Expanding target conditions to include ADHD, COPD, and sleep disorders
Obviousness Reasoning
Finite set of identifiable conditions where oxygen metabolism and cellular adaptation play critical therapeutic roles
Source Patent Element
Pharmaceutical composition containing HIF prolyl hydroxylase inhibitor
PTD Variation
Monitoring and adjusting dosage based on individual performance metrics
Obviousness Reasoning
Routine optimization technique in pharmaceutical development, representing standard practice of personalized medicine approaches
Source Patent Element
Pharmacological intervention targeting metabolic pathways
PTD Variation
Exploring alternative embodiments across different disease states
Obviousness Reasoning
Systematic exploration of a known molecular mechanism across related physiological domains represents expected scientific progression
35 U.S.C. § 103 Summary: Based on US Patent 11857543's disclosure of HIF prolyl hydroxylase inhibitor mechanisms, the present publication demonstrates that a person of ordinary skill in the art would find the expanded therapeutic applications and performance enhancement methods obvious and predictable extensions of the existing technological framework, thereby rendering subsequent claims in these domains anticipated and non-patentable under standard obviousness criteria.

Original Patent Information

Patent NumberUS 11,857,543
TitleCompositions and methods for treating anemia
Assignee(s)Akebia Therapeutics, Inc.